secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0000950170-23-008122
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q4 2022 net loss $29.9M; cash $257.7M; ADI-001 ORR 75%
-----------------------------------------------------------------

- Q4 net loss $29.9M ($0.72 per share) vs $15.8M in Q4 2021; FY net loss $69.8M.
- Cash and equivalents $257.7M at Dec 31, 2022; expected runway into H1 2025.
- R&D expenses Q4 $25.0M, up 70% YoY; G&A $6.6M, flat.
- ADI-001 Phase 1 data: 75% ORR, 69% CR across doses; pivotal study plan in Q2 2023.
- IND for ADI-925 (CAd gamma delta T cell) expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023008122/0000950170-23-008122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017023008122/acet-20230315.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer